Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison…
Schizophrenia, “just the facts” 4. Clinical features and conceptualization
Schizophrenia, “Just the Facts”: What we know in 2008 Part 1: Overview
Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: Data from the CATIE schizophrenia trial sample at baseline
Schizophrenia, “Just the Facts” What we know in 2008. 2. Epidemiology and etiology
A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls
Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles
- H. Nasrallah
- Psychology, MedicineMolecular Psychiatry
A review examines the potential contribution of different receptors to metabolic side effects associated with atypical antipsychotic treatment for all seven agents currently marketed in the United States and another agent in clinical development at the time of this publication.
Schizophrenia, “just the facts”: What we know in 2008 Part 3: Neurobiology
The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial: Clinical comparison of subgroups with and without the metabolic syndrome